Morbidity and mortality associated with antireflux surgery with or without paraesophogeal hernia: a large ACS NSQIP analysis.
ABSTRACT Surgical repair of paraesophageal hernias (PEH) represents a considerable technical challenge in patients who are older and have multiple comorbidities. We sought to identify factors associated with increased rates of mortality and morbidity in these patients.
We performed a retrospective analysis of the National Surgical Quality Improvement Program from 2005 through 2007. Patients who underwent an antireflux operation or repair of PEH and with a primary diagnosis of PEH or GERD were included. Primary outcome was 30-day mortality. Secondary outcomes included intraoperative blood transfusion (BT) and standard comorbidities. Multivariate analyses were performed, adjusting for factors of age and BMI.
A total of 3518 patients were identified, including 1290 PEH patients. Compared to GERD patients, PEH patients were significantly older and had more comorbidities. On adjusted analysis for PEH patients only, BT and age ≥70 years were significantly associated with multiple outcome variables, including pulmonary complications and venous thromboembolism (VTE), but had no association with mortality. BMI was not found to be associated with any of our outcome measures.
Despite higher rates of complications, notably pulmonary and VTE, PEH can be repaired in the elderly with mortality rates comparable to those in younger populations. BMI does not adversely impact any short-term outcome measures in patients undergoing PEH repair.
Article: Perioperative risk of laparoscopic fundoplication: safer than previously reported-analysis of the American College of Surgeons National Surgical Quality Improvement Program 2005 to 2009.[show abstract] [hide abstract]
ABSTRACT: Several prospective randomized controlled trials show equal effectiveness of surgical fundoplication and proton pump inhibitor therapy for the treatment of gastroesophageal reflux disease. Despite this compelling evidence of its efficacy, surgical antireflux therapy is underused, occurring in a very small proportion of patients with gastroesophageal reflux disease. An important reason for this is the perceived morbidity and mortality associated with surgical intervention. Published data report perioperative morbidity between 3% and 21% and mortality of 0.2% and 0.5%, and current data are uncommon, largely from previous decades, and almost exclusively single institutional. The study population included all patients in the American College of Surgeons National Surgical Quality Improvement Program database from 2005 through 2009 who underwent laparoscopic fundoplication with or without related postoperative ICD-9 codes. Comorbidities, intraoperative occurrences, and 30-day postoperative outcomes were collected and logged into statistical software for appropriate analysis. Postoperative occurrences were divided into overall and serious morbidity. A total of 7,531 fundoplications were identified. Thirty-five percent of patients were younger than 50 years old, 47.1% were 50 to 69 years old, and 16.8% were older than 69 years old. Overall, 30-day mortality was 0.19% and morbidity was 3.8%. Thirty-day mortality was rare in patients younger than age 70 years, occurring in 5 of 10,000 (0.05%). Mortality increased to 8 of 1,000 (0.8%) in patients older than 70 years (p < 0.0001). Complications occurred in 2.2% of patients younger than 50 years, 3.8% of those 50 to 69 years, and 7.3% of patients older than 69 years. Serious complications occurred in 8 of 1,000 (0.8%) patients younger than 50 years, 1.8% in patients 50 to 69 years, and 3.9% of those older than 69 years. Analysis of this large cohort demonstrates remarkably low 30-day morbidity and mortality of laparoscopic fundoplication. This is particularly true in patients younger than 70 years, who are likely undergoing fundoplication for gastroesophageal reflux disease. These data suggest that surgical therapy carries an acceptable risk profile.Journal of the American College of Surgeons 05/2012; 215(1):61-8; discussion 68-9. · 4.55 Impact Factor